What Does Aptorum Group (APM) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks & Headquarters Summary
APM (Aptorum Group) is a Hong Kong-headquartered, clinical-stage micro-cap biopharmaceutical holding company that simultaneously develops oncology drugs, antibiotics, and rapid pathogen diagnostics through a drug repurposing strategy.
SubscribeAPM is the NASDAQ ticker for Aptorum Group, a clinical-stage biopharmaceutical holding company headquartered in Hong Kong. Rather than building new drugs from scratch, the company follows a strategy of repurposing existing drugs and active ingredients for new indications (drug repurposing), and its distinctive feature is running a broad pipeline covering oncology, infectious diseases, and diagnostics simultaneously.
There are three core candidates. SACT-1, which targets oncology indications including neuroblastoma (a pediatric nervous-system cancer); ALS-4, which targets bacterial infections such as Staphylococcus aureus, Mycobacterium tuberculosis, and Pseudomonas aeruginosa; and RPIDD, a liquid-biopsy-based rapid pathogen diagnostic platform. The company has announced that both its oncology and antibiotic candidates have completed Phase 1 clinical trials.
💰 How does it make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| SACT-1 (Oncology) | Phase 1 completed | Drug-repurposing-based oncology therapy targeting pediatric and solid tumors such as neuroblastoma |
| ALS-4 (Antibiotic) | Phase 1 completed | Targets gram-positive bacterial infections including Staphylococcus aureus, Mycobacterium tuberculosis, and Pseudomonas aeruginosa |
| RPIDD (Diagnostics) | Preclinical | Liquid-biopsy-based rapid pathogen diagnostic platform |
| Other Pipeline | Preclinical | Multiple candidates including SACT-COV19, ALS-1/2/3, NLS-1 (endometriosis), DLS-1~3, and CLS-1 (obesity) |
As a clinical-stage biotech, APM has no meaningful product revenue, and the bulk of its revenue is generated from research collaborations, service fees, and small ancillary income. Revenue growth is around -, operating margin is -, and net margin is -, making losses the norm. In other words, the company's value is assessed not on short-term profitability but on the "option value of the pipeline."
Market Cap and Company ScaleThe market cap is $5.7M, approximately About 0% of Samsung Electronics' market cap. The company employs 2 people people.
APM's market cap is $5.7M, placing it at roughly About 0% of Samsung Electronics' market cap, making it an ultra-small-cap stock. Headcount stands at approximately 2 people, and because the company frequently issues new shares and convertible bonds to fund operations, changes in shares outstanding and capital structure need to be monitored together.
📈 Aptorum Group Outlook and Stock Price Action
1-Year Price Performance
Analyst Consensus
52-Week Price Range✅ Investor Checklist
APM is a stock suited to investors who want to bet on a multi-pipeline micro-cap biotech theme. Before buying, three areas should be reviewed together: clinical, capital, and licensing.
| Checklist | What to verify | Current status |
|---|---|---|
| 🧪 Progress of core candidates' clinical trials | Phase 2 entry timeline and data readouts for SACT-1 and ALS-4 | Company IR and press releases |
| 💧 Capital-raising structure | Frequency of new-share and convertible bond issuance and trends in shares outstanding | 8-K and 6-K filings |
| 🤝 Licensing deals | Status of co-development and licensing agreements with big pharma and mid-sized pharma companies | Monitoring press releases |
| 📑 Streamlining of other pipeline programs | Whether non-core candidates are divested, discontinued, or deprioritized | Quarterly reports |
The biggest risks are clinical failure and dilution from capital raises. In addition, given that the company carries a pipeline that is too large for its size, limited resources may be spread too thin, and there is a risk that no candidate reaches decisive data while funds simply burn down; this should also be reviewed.
APM is a clinical-stage micro-cap biotech built around the concept of "drug repurposing plus a multi-pipeline." In a portfolio, it makes sense to limit it to a satellite allocation within the biotech theme, and to gradually adjust the weight as momentum signals such as Phase 2 entry of core candidates and visibility on licensing deals accumulate.
On US Stock Today's real-time dashboard, check Aptorum Group's live quotes, technical indicators, and peer comparison at a glance.
Subscribe Today's 5 AI picks, all free